* If you want to update the article please login/register
Following the session today, you will be given details on the findings of the screening tests you underwent at BCM to see if you have a recent depressive disorder or other psychiatric disorders. If you're accepted to Group 1, you will be given counseling to help you develop emotional coping skills to help with anxiety and negative feelings that may affect your ability to quit smoking. If you are in Group 1, you will receive information about how cigarette smoking is a learned habit and a physical dependency as well as how the habit can be broken down. To help you recognize situations that are high risk of smoking and help you create behavioral coping strategies to minimize the chances of smoking in those situations, you'll get support. If you are in Group 2, you will receive information about how cigarette smoking is a learned habit and a physical dependency as well as how the habit can be broken down. In those situations, you will also be able to get to know situations that are high risk for smoking and help you develop behavioral coping strategies to reduce the chances of smoking in those situations. If you are unable to attend your end-of-care, 3-month, or 6-month visits, you may be asked to submit a saliva sample to determine the amount of cotinine in your blood, a chemical that promotes nicotine degradation during smoking. If you are currently smoking, you will be given more information on how you can obtain additional assistance to quit smoking at the last medical visit and at the 3-month and 6-month follow-up visits. If you persist to have a current depressive disorder, you will be given additional information about this disorder, as well as details on how to obtain medical care for your depressive disorder. If you want to receive medical attention for your depressive disorder at that time, the investigators will make a recommendation for therapy. The videotapes will be used to aid the investigators in making sure the counselors are following the correct therapy protocols, and may be used in future studies to help the investigators better understand the mood control and health education treatments. At the baseline visit, you will be asked to provide the name and address of two individuals you feel comfortable with updated contact details on you so that the research team can stay in touch with you through the course of your research and into the long period of time between your end of care visit and the 3- and 6-month follow-up visits.
Source link: https://clinicaltrials.gov/ct2/show/NCT00494728
Part 1: Advice on How Patients Can Be Certain About Smoking Acceptance and Commitment Therapy is designed to assist patients in reducing the way they react to feelings and thoughts that lead them to want to smoke. For this analysis, the information you collect in the Tobacco Treatment Program questionnaires about anxiety, depression, alcohol use, sleeping disorders, nicotine dependence, and smoking will be used, so you do not have to fill out these questionnaires twice. The study counselors' qualification dates and other research requirements will determine the organization you are in. Varenicline as Standard Care: Participants in both groups will be treated with vaping through the Tobacco Treatment Program, according to Varenicline. Your first dose will be at least two weeks before the quit date, and you can continue taking vaping until 8 weeks after the quit date. With you, the Tobacco Treatment Program workers will address the risks of vaping with you. During the 12 weeks following your screening/baseline visit, you will have 6 visits with a study consultant. Also on this visit, the research staff may ask you to provide a saliva sample that will be used to determine if and how much you've smoked. If you do not complete all six of the counseling sessions, the research staff will call and ask you what made it impossible for you to finish the counseling sessions. The videotapes will be used to help the study staff ensure that the study counselors are following the correct therapeutic protocol. The study consultants will investigate the tapes and determine how well the study counselors follow therapy protocols. Safety Tips: Quitting smoking can have side effects that can influence your mental and emotional wellbeing. For your protection, the research counselor and study chair will be looking for any indications that you may be experiencing these side effects. If the study counselor or research chair suspect that you may be experiencing emotional difficulties or depression, they may decide to recommend that you be treated for it. If they suspect you are at risk of being a threat to yourself, you will be welcomed by the study chair right away, and if appropriate, you will be referred to consult with a Tobacco Treatment Program psychiatrist. You may be asked to submit a saliva sample that will be used to determine when and how much you have smoked. Acceptance and Commitment Therapy is designed to assist patients in transforming the way they respond to emotions and thoughts that cause them to want to smoke in Part 2. The information you submitted in the Tobacco Treatment Program questionnaires about anxiety, depression, alcohol use, sleeping disorders, nicotine dependence, and smoking will be used for this research so that you do not have to fill out these questionnaires twice. Participants in both groups will be offered varenicline through the Tobacco Treatment Service Program, according to Varenicline as Standard Care: Participants in both groups will receive varenicline. Varenicline is the recommended drug used in the Tobacco Treatment Program, according to Varenicline. With you, The Tobacco Treatment Program workers will discuss the risks of vaping with you. Counseling Visits: During the 12 weeks after your screening/baseline visit, you will have 6 visits with a study advisor. The last counseling visit may require you to provide a saliva sample that will be used to determine when and how much you have smoked. The videotapes will be used to help the study assistants ensure that the study counselors are following the correct therapy methods. The study consultants will examine the tapes and determine whether or well the study counselors follow therapy procedures. The study consultants will review the tapes and determine how well the study counselors follow therapy protocols. Safety Tips: Quitting smoking can cause side effects that impact your physical and emotional stability. If the research researcher or analysis chair suspects that you may be experiencing emotional difficulties or depression, they may decide to recommend that you be treated for it. If they suspect you are at risk of being a danger to yourself, you will be welcomed by the research chair right away, and if appropriate, you will be referred to consult with a Tobacco Treatment Program psychiatrist. At these visits, the research team may request that you provide a saliva sample that will be used to determine whether or how much you have smoked. This includes 12 people who were interviewed before Part 1 opens, 20 participants in Part 1, and 76 participants in Part 2.
Source link: https://clinicaltrials.gov/ct2/show/NCT01098955
Cigarette smoking is the most common preventable cause of premature death worldwide. However, smoking is a difficult drug to quit, and despite existing smoking cessation services, quit rates in the real-life setting are low. In the case of novel pharmacotherapeutic approaches for smoking cessation, the putative role of GLP-1 analogues in nicotine reward control and its weight reduction results may be of utmost importance. "fMRI" is a scientific term that refers to the reward system, and this subgroup examines whether Dulaglutide treatment reduces hunger and therefore functional brain stimulation. It is to investigate the effects of Dulaglutide therapy on functional neuronal changes in smokers who want to avoid smoking. "Energy": the subpoena in this subset of patients enrolled in the main trial is intended to investigate the effect of Dulaglutide on REE and other parameters related to energy metabolism.
Source link: https://clinicaltrials.gov/ct2/show/NCT03204396
AIM 2: Participants attend focus groups for over 1-1. 5 hours. Participants are followed up at three months after the completion of the Aim 3 research study.
Source link: https://clinicaltrials.gov/ct2/show/NCT05304390
We'll do a 4-arm randomized trial comparing 4 interventions to promote sustained, biochemically confirmed smoking cessation for six months among smokers in underserved demographic groups. Following the participants' chosen quit dates, the most significant result will be biochemically confirmed sustained abstinence from smoking nicotine for six months.
Source link: https://clinicaltrials.gov/ct2/show/NCT04798664
Numerous studies comparing smokers to non-smokers have shown effects on spermatogenesis and the male gamete's quality. In vain, fertility success rates have been reduced in smokers and in natural procreation, the time required to conceive seems to have been extended in the smoker. Tobacco raises the oxydation of DNA. As has been reported in several studies, smoking exposure raises the percentage of spermatozoa with missing DNA or defective chromatin, as well as gametes aneuploidy. The effect of the term is unclear in this case. The explorative analysis that the investigators propose will determine the time needed to repair the sperm abnormalities, as well as the DNA of the gametes produced by the smoking process.
Source link: https://clinicaltrials.gov/ct2/show/NCT03552081
Given the high prevalence of cigarette use among PLWH and the benefit of smoke cessation, there is urgent need for swift intervention to reduce tobacco use rates. This research report will examine smoking habits in people living with HIV and the subsequent effectiveness of mHealth efforts for improving tobacco cessation in PLWH, given the urgency of improving smoking cessation in PLWH and the promise of mHealth devices.
Source link: https://clinicaltrials.gov/ct2/show/NCT04808609
In the BA+VLNC condition, smokers will switch to nicotine cigarettes when wearing a 21 mg/d nicotine patch for 5 weeks before to their quit date. The same pharmacological pretreatment will be administered to the VLNC Only group, but rather than BA, smokers in the VLNC Only group will receive standard counseling and health education. Participants will also be sent follow-up phone calls at 6 months and 12 months post-quit to determine smoking status.
Source link: https://clinicaltrials.gov/ct2/show/NCT02927847
Evaluate a multi-faceted training scheme to increase short-term smoking cessation rates and sustained abstinence among 1,114 enrolled smokers in community-based lung cancer screening studies; Identify the adoption and enhancement of the evidence-based nicotine cessation policies in 26 community-based LDCT lung cancer screening services; and Develop and evaluate an implementation toolkit for implementing evidence-based tobacco cessation strategies in community-based lung cancer screening services. Quantitative survey results and saliva samples will be collected from smoking patients undergoing screening within these programs.
Source link: https://clinicaltrials.gov/ct2/show/NCT03291587
To determine the comparative effectiveness of Behavioral Activation Therapy for Smoking plus nicotine replacement therapy in comparison to standard cessation therapy plus NRT on high reward sensitivity smokers and low reward sensitive smokers, sees. Patients receive a NRT patch every 8 weeks, according to GROUP I. For 8 sessions, patients are referred to individual behavioral intervention sessions containing behavioral modification techniques for smoking cessation and health education information. Patients receive a NRT patch every 8 weeks, according to GROUP II.
Source link: https://clinicaltrials.gov/ct2/show/NCT02697227
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions